Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.

Oka, Y et al.·Current medicinal chemistry·2006·
RPEP-011752006RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Published In:
Current medicinal chemistry, 13(20), 2345-52 (2006)
Database ID:
RPEP-01175

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-01175·https://rethinkpeptides.com/research/RPEP-01175

APA

Oka, Y; Tsuboi, A; Kawakami, M; Elisseeva, O A; Nakajima, H; Udaka, K; Kawase, I; Oji, Y; Sugiyama, H. (2006). Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.. Current medicinal chemistry, 13(20), 2345-52.

MLA

Oka, Y, et al. "Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.." Current medicinal chemistry, 2006.

RethinkPeptides

RethinkPeptides Research Database. "Development of WT1 peptide cancer vaccine against hematopoie..." RPEP-01175. Retrieved from https://rethinkpeptides.com/research/oka-2006-development-of-wt1-peptide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.